AstraZeneca
Cambridge ,
Cambridgeshire CB2 0AA
United Kingdom
- Home
- Companies
- AstraZeneca
- Products
- Model AZD3366 - Phase I - ...
Model AZD3366 - Phase I - Cardiovascular Disease
From Cardiovascular, Renal & Metabolism
Mechanism: CD39L3. Area under investigation: cardiovascular disease. Date commenced phase: Q4 2020. Estimated Filing Acceptance: Country:US, EU, Japan, China, Additional information: Molecule size: Small molecule. Status change:
-
Most popular related searches
Customer reviews
No reviews were found for Model AZD3366 - Phase I - Cardiovascular Disease. Be the first to review!